Surrozen, Inc.
Surrozen, Inc. (SRZNW) Stock Competitors & Peer Comparison
See (SRZNW) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SRZNW | $0.02 | +11.70% | 157K | N/A | -$5.70 | N/A |
| VRTX | $424.36 | -1.28% | 107.9B | 25.18 | $16.85 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $702.27 | -0.98% | 72.4B | 17.15 | $40.96 | +0.51% |
| ARGX | $794.70 | -2.02% | 49.2B | 40.56 | $19.59 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $301.11 | +1.07% | 40.2B | 75.83 | $3.97 | N/A |
| RVMD | $147.21 | -0.47% | 31.3B | -24.74 | -$5.95 | N/A |
| INSM | $139.44 | -0.41% | 30.1B | -21.69 | -$6.43 | N/A |
| UTHR | $572.20 | -1.55% | 25.1B | 20.54 | $27.86 | N/A |
Stock Comparison
SRZNW vs VRTX Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, VRTX has a market cap of 107.9B. Regarding current trading prices, SRZNW is priced at $0.02, while VRTX trades at $424.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas VRTX's P/E ratio is 25.18. In terms of profitability, SRZNW's ROE is +6.11%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, SRZNW is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check VRTX's competition here
SRZNW vs VRNA Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, SRZNW is priced at $0.02, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas VRNA's P/E ratio is -102.80. In terms of profitability, SRZNW's ROE is +6.11%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, SRZNW is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check VRNA's competition here
SRZNW vs REGN Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, REGN has a market cap of 72.4B. Regarding current trading prices, SRZNW is priced at $0.02, while REGN trades at $702.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas REGN's P/E ratio is 17.15. In terms of profitability, SRZNW's ROE is +6.11%, compared to REGN's ROE of +0.14%. Regarding short-term risk, SRZNW is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check REGN's competition here
SRZNW vs ARGX Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, ARGX has a market cap of 49.2B. Regarding current trading prices, SRZNW is priced at $0.02, while ARGX trades at $794.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas ARGX's P/E ratio is 40.56. In terms of profitability, SRZNW's ROE is +6.11%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, SRZNW is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check ARGX's competition here
SRZNW vs SGEN Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, SRZNW is priced at $0.02, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas SGEN's P/E ratio is -57.19. In terms of profitability, SRZNW's ROE is +6.11%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, SRZNW is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check SGEN's competition here
SRZNW vs ALNY Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, ALNY has a market cap of 40.2B. Regarding current trading prices, SRZNW is priced at $0.02, while ALNY trades at $301.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas ALNY's P/E ratio is 75.83. In terms of profitability, SRZNW's ROE is +6.11%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, SRZNW is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check ALNY's competition here
SRZNW vs RVMD Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, RVMD has a market cap of 31.3B. Regarding current trading prices, SRZNW is priced at $0.02, while RVMD trades at $147.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas RVMD's P/E ratio is -24.74. In terms of profitability, SRZNW's ROE is +6.11%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, SRZNW is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check RVMD's competition here
SRZNW vs INSM Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, INSM has a market cap of 30.1B. Regarding current trading prices, SRZNW is priced at $0.02, while INSM trades at $139.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas INSM's P/E ratio is -21.69. In terms of profitability, SRZNW's ROE is +6.11%, compared to INSM's ROE of -1.68%. Regarding short-term risk, SRZNW is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check INSM's competition here
SRZNW vs UTHR Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, UTHR has a market cap of 25.1B. Regarding current trading prices, SRZNW is priced at $0.02, while UTHR trades at $572.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas UTHR's P/E ratio is 20.54. In terms of profitability, SRZNW's ROE is +6.11%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, SRZNW is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check UTHR's competition here
SRZNW vs BNTX Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, BNTX has a market cap of 24B. Regarding current trading prices, SRZNW is priced at $0.02, while BNTX trades at $95.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas BNTX's P/E ratio is -17.32. In terms of profitability, SRZNW's ROE is +6.11%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, SRZNW is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check BNTX's competition here
SRZNW vs RPRX Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, RPRX has a market cap of 21.6B. Regarding current trading prices, SRZNW is priced at $0.02, while RPRX trades at $50.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas RPRX's P/E ratio is 28.34. In terms of profitability, SRZNW's ROE is +6.11%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, SRZNW is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check RPRX's competition here
SRZNW vs ROIV Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, ROIV has a market cap of 20.3B. Regarding current trading prices, SRZNW is priced at $0.02, while ROIV trades at $28.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas ROIV's P/E ratio is -24.21. In terms of profitability, SRZNW's ROE is +6.11%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, SRZNW is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check ROIV's competition here
SRZNW vs BGNE Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, SRZNW is priced at $0.02, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas BGNE's P/E ratio is -22.55. In terms of profitability, SRZNW's ROE is +6.11%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, SRZNW is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check BGNE's competition here
SRZNW vs INCY Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, INCY has a market cap of 19.5B. Regarding current trading prices, SRZNW is priced at $0.02, while INCY trades at $97.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas INCY's P/E ratio is 13.73. In terms of profitability, SRZNW's ROE is +6.11%, compared to INCY's ROE of +0.29%. Regarding short-term risk, SRZNW is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check INCY's competition here
SRZNW vs DNA-WT Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, SRZNW is priced at $0.02, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, SRZNW's ROE is +6.11%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, SRZNW is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check DNA-WT's competition here
SRZNW vs MRNA Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, MRNA has a market cap of 18.5B. Regarding current trading prices, SRZNW is priced at $0.02, while MRNA trades at $46.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas MRNA's P/E ratio is -6.44. In terms of profitability, SRZNW's ROE is +6.11%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, SRZNW is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check MRNA's competition here
SRZNW vs GMAB Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, GMAB has a market cap of 17B. Regarding current trading prices, SRZNW is priced at $0.02, while GMAB trades at $27.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas GMAB's P/E ratio is 17.88. In terms of profitability, SRZNW's ROE is +6.11%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, SRZNW is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check GMAB's competition here
SRZNW vs ASND Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, ASND has a market cap of 13.8B. Regarding current trading prices, SRZNW is priced at $0.02, while ASND trades at $225.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas ASND's P/E ratio is -51.19. In terms of profitability, SRZNW's ROE is +6.11%, compared to ASND's ROE of +1.28%. Regarding short-term risk, SRZNW is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check ASND's competition here
SRZNW vs SMMT Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, SMMT has a market cap of 13.6B. Regarding current trading prices, SRZNW is priced at $0.02, while SMMT trades at $17.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas SMMT's P/E ratio is -11.03. In terms of profitability, SRZNW's ROE is +6.11%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, SRZNW is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check SMMT's competition here
SRZNW vs BBIO Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, BBIO has a market cap of 13.3B. Regarding current trading prices, SRZNW is priced at $0.02, while BBIO trades at $68.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas BBIO's P/E ratio is -18.19. In terms of profitability, SRZNW's ROE is +6.11%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, SRZNW is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check BBIO's competition here
SRZNW vs JAZZ Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, JAZZ has a market cap of 13.3B. Regarding current trading prices, SRZNW is priced at $0.02, while JAZZ trades at $212.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas JAZZ's P/E ratio is -35.44. In terms of profitability, SRZNW's ROE is +6.11%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, SRZNW is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check JAZZ's competition here
SRZNW vs KRTX Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, SRZNW is priced at $0.02, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas KRTX's P/E ratio is -28.09. In terms of profitability, SRZNW's ROE is +6.11%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, SRZNW is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check KRTX's competition here
SRZNW vs IONS Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, IONS has a market cap of 12.4B. Regarding current trading prices, SRZNW is priced at $0.02, while IONS trades at $75.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas IONS's P/E ratio is -37.43. In terms of profitability, SRZNW's ROE is +6.11%, compared to IONS's ROE of -0.59%. Regarding short-term risk, SRZNW is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check IONS's competition here
SRZNW vs MDGL Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, MDGL has a market cap of 11.5B. Regarding current trading prices, SRZNW is priced at $0.02, while MDGL trades at $502.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas MDGL's P/E ratio is -39.05. In terms of profitability, SRZNW's ROE is +6.11%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, SRZNW is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check MDGL's competition here
SRZNW vs AXSM Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, AXSM has a market cap of 11.4B. Regarding current trading prices, SRZNW is priced at $0.02, while AXSM trades at $223.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas AXSM's P/E ratio is -60.60. In terms of profitability, SRZNW's ROE is +6.11%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, SRZNW is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check AXSM's competition here
SRZNW vs EXEL Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, EXEL has a market cap of 11.3B. Regarding current trading prices, SRZNW is priced at $0.02, while EXEL trades at $44.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas EXEL's P/E ratio is 15.99. In terms of profitability, SRZNW's ROE is +6.11%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, SRZNW is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check EXEL's competition here
SRZNW vs RNAM Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, SRZNW is priced at $0.02, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas RNAM's P/E ratio is -17.39. In terms of profitability, SRZNW's ROE is +6.11%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, SRZNW is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check RNAM's competition here
SRZNW vs ARWR Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, ARWR has a market cap of 10.5B. Regarding current trading prices, SRZNW is priced at $0.02, while ARWR trades at $74.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas ARWR's P/E ratio is 46.83. In terms of profitability, SRZNW's ROE is +6.11%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, SRZNW is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check ARWR's competition here
SRZNW vs BMRN Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, BMRN has a market cap of 10.2B. Regarding current trading prices, SRZNW is priced at $0.02, while BMRN trades at $53.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas BMRN's P/E ratio is 38.30. In terms of profitability, SRZNW's ROE is +6.11%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, SRZNW is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check BMRN's competition here
SRZNW vs RXDX Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, SRZNW is priced at $0.02, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas RXDX's P/E ratio is -56.47. In terms of profitability, SRZNW's ROE is +6.11%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, SRZNW is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check RXDX's competition here
SRZNW vs CYTK Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, CYTK has a market cap of 9.5B. Regarding current trading prices, SRZNW is priced at $0.02, while CYTK trades at $77.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas CYTK's P/E ratio is -11.79. In terms of profitability, SRZNW's ROE is +6.11%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, SRZNW is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check CYTK's competition here
SRZNW vs TECH Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, TECH has a market cap of 8.9B. Regarding current trading prices, SRZNW is priced at $0.02, while TECH trades at $56.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas TECH's P/E ratio is 106.94. In terms of profitability, SRZNW's ROE is +6.11%, compared to TECH's ROE of +0.04%. Regarding short-term risk, SRZNW is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check TECH's competition here
SRZNW vs IMGN Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, SRZNW is priced at $0.02, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas IMGN's P/E ratio is -111.55. In terms of profitability, SRZNW's ROE is +6.11%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, SRZNW is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check IMGN's competition here
SRZNW vs KRYS Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, KRYS has a market cap of 8.4B. Regarding current trading prices, SRZNW is priced at $0.02, while KRYS trades at $284.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas KRYS's P/E ratio is 38.16. In terms of profitability, SRZNW's ROE is +6.11%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, SRZNW is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check KRYS's competition here
SRZNW vs BPMC Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, SRZNW is priced at $0.02, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas BPMC's P/E ratio is -51.58. In terms of profitability, SRZNW's ROE is +6.11%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, SRZNW is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check BPMC's competition here
SRZNW vs CERE Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, SRZNW is priced at $0.02, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas CERE's P/E ratio is -16.47. In terms of profitability, SRZNW's ROE is +6.11%, compared to CERE's ROE of -0.72%. Regarding short-term risk, SRZNW is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check CERE's competition here
SRZNW vs ABVX Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, ABVX has a market cap of 8.1B. Regarding current trading prices, SRZNW is priced at $0.02, while ABVX trades at $123.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas ABVX's P/E ratio is -21.86. In terms of profitability, SRZNW's ROE is +6.11%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, SRZNW is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check ABVX's competition here
SRZNW vs PCVX Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, PCVX has a market cap of 8B. Regarding current trading prices, SRZNW is priced at $0.02, while PCVX trades at $55.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas PCVX's P/E ratio is -9.89. In terms of profitability, SRZNW's ROE is +6.11%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, SRZNW is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check PCVX's competition here
SRZNW vs HALO Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, HALO has a market cap of 7.8B. Regarding current trading prices, SRZNW is priced at $0.02, while HALO trades at $65.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas HALO's P/E ratio is 25.73. In terms of profitability, SRZNW's ROE is +6.11%, compared to HALO's ROE of +0.93%. Regarding short-term risk, SRZNW is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check HALO's competition here
SRZNW vs IBRX Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, IBRX has a market cap of 7.8B. Regarding current trading prices, SRZNW is priced at $0.02, while IBRX trades at $7.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas IBRX's P/E ratio is -18.96. In terms of profitability, SRZNW's ROE is +6.11%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, SRZNW is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check IBRX's competition here
SRZNW vs NUVL Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, NUVL has a market cap of 7.5B. Regarding current trading prices, SRZNW is priced at $0.02, while NUVL trades at $101.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas NUVL's P/E ratio is -17.35. In terms of profitability, SRZNW's ROE is +6.11%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, SRZNW is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check NUVL's competition here
SRZNW vs MTSR Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, SRZNW is priced at $0.02, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas MTSR's P/E ratio is -23.58. In terms of profitability, SRZNW's ROE is +6.11%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, SRZNW is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check MTSR's competition here
SRZNW vs PRAX Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, PRAX has a market cap of 7B. Regarding current trading prices, SRZNW is priced at $0.02, while PRAX trades at $333.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas PRAX's P/E ratio is -24.73. In terms of profitability, SRZNW's ROE is +6.11%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, SRZNW is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check PRAX's competition here
SRZNW vs CELC Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, CELC has a market cap of 6.8B. Regarding current trading prices, SRZNW is priced at $0.02, while CELC trades at $141.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas CELC's P/E ratio is -37.46. In terms of profitability, SRZNW's ROE is +6.11%, compared to CELC's ROE of -2.03%. Regarding short-term risk, SRZNW is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check CELC's competition here
SRZNW vs MRUS Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, SRZNW is priced at $0.02, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas MRUS's P/E ratio is -17.05. In terms of profitability, SRZNW's ROE is +6.11%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, SRZNW is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check MRUS's competition here
SRZNW vs KYMR Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, KYMR has a market cap of 6.8B. Regarding current trading prices, SRZNW is priced at $0.02, while KYMR trades at $82.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas KYMR's P/E ratio is -23.11. In terms of profitability, SRZNW's ROE is +6.11%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, SRZNW is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check KYMR's competition here
SRZNW vs ACLX Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, SRZNW is priced at $0.02, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas ACLX's P/E ratio is -28.27. In terms of profitability, SRZNW's ROE is +6.11%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, SRZNW is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check ACLX's competition here
SRZNW vs RETA Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, SRZNW is priced at $0.02, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas RETA's P/E ratio is -66.29. In terms of profitability, SRZNW's ROE is +6.11%, compared to RETA's ROE of +0.47%. Regarding short-term risk, SRZNW is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check RETA's competition here
SRZNW vs PTGX Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, PTGX has a market cap of 6.3B. Regarding current trading prices, SRZNW is priced at $0.02, while PTGX trades at $99.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas PTGX's P/E ratio is -48.43. In terms of profitability, SRZNW's ROE is +6.11%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, SRZNW is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check PTGX's competition here
SRZNW vs RYTM Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, RYTM has a market cap of 6.3B. Regarding current trading prices, SRZNW is priced at $0.02, while RYTM trades at $92.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas RYTM's P/E ratio is -29.68. In terms of profitability, SRZNW's ROE is +6.11%, compared to RYTM's ROE of -2.04%. Regarding short-term risk, SRZNW is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check RYTM's competition here
SRZNW vs BLTE Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, BLTE has a market cap of 6.2B. Regarding current trading prices, SRZNW is priced at $0.02, while BLTE trades at $154.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas BLTE's P/E ratio is -66.73. In terms of profitability, SRZNW's ROE is +6.11%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, SRZNW is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check BLTE's competition here
SRZNW vs ALKS Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, ALKS has a market cap of 6B. Regarding current trading prices, SRZNW is priced at $0.02, while ALKS trades at $36.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas ALKS's P/E ratio is 25.36. In terms of profitability, SRZNW's ROE is +6.11%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, SRZNW is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check ALKS's competition here
SRZNW vs COGT Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, COGT has a market cap of 6B. Regarding current trading prices, SRZNW is priced at $0.02, while COGT trades at $36.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas COGT's P/E ratio is -17.13. In terms of profitability, SRZNW's ROE is +6.11%, compared to COGT's ROE of -0.83%. Regarding short-term risk, SRZNW is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check COGT's competition here
SRZNW vs CNTA Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, CNTA has a market cap of 5.9B. Regarding current trading prices, SRZNW is priced at $0.02, while CNTA trades at $39.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas CNTA's P/E ratio is -27.16. In terms of profitability, SRZNW's ROE is +6.11%, compared to CNTA's ROE of -0.51%. Regarding short-term risk, SRZNW is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check CNTA's competition here
SRZNW vs TGTX Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, TGTX has a market cap of 5.8B. Regarding current trading prices, SRZNW is priced at $0.02, while TGTX trades at $36.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas TGTX's P/E ratio is 13.03. In terms of profitability, SRZNW's ROE is +6.11%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, SRZNW is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check TGTX's competition here
SRZNW vs CGON Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, CGON has a market cap of 5.7B. Regarding current trading prices, SRZNW is priced at $0.02, while CGON trades at $67.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas CGON's P/E ratio is -32.29. In terms of profitability, SRZNW's ROE is +6.11%, compared to CGON's ROE of -0.23%. Regarding short-term risk, SRZNW is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check CGON's competition here
SRZNW vs IMVT Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, IMVT has a market cap of 5.7B. Regarding current trading prices, SRZNW is priced at $0.02, while IMVT trades at $27.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas IMVT's P/E ratio is -10.42. In terms of profitability, SRZNW's ROE is +6.11%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, SRZNW is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check IMVT's competition here
SRZNW vs CDTX Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, SRZNW is priced at $0.02, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas CDTX's P/E ratio is -19.77. In terms of profitability, SRZNW's ROE is +6.11%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, SRZNW is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check CDTX's competition here
SRZNW vs ABCM Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, SRZNW is priced at $0.02, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, SRZNW's ROE is +6.11%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, SRZNW is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check ABCM's competition here
SRZNW vs ISEE Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, SRZNW is priced at $0.02, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas ISEE's P/E ratio is -22.44. In terms of profitability, SRZNW's ROE is +6.11%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, SRZNW is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check ISEE's competition here
SRZNW vs CORT Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, CORT has a market cap of 5.5B. Regarding current trading prices, SRZNW is priced at $0.02, while CORT trades at $51.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas CORT's P/E ratio is 146.69. In terms of profitability, SRZNW's ROE is +6.11%, compared to CORT's ROE of +0.08%. Regarding short-term risk, SRZNW is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check CORT's competition here
SRZNW vs SRRK Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, SRRK has a market cap of 5.4B. Regarding current trading prices, SRZNW is priced at $0.02, while SRRK trades at $47.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas SRRK's P/E ratio is -14.34. In terms of profitability, SRZNW's ROE is +6.11%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, SRZNW is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check SRRK's competition here
SRZNW vs PTCT Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, PTCT has a market cap of 5.4B. Regarding current trading prices, SRZNW is priced at $0.02, while PTCT trades at $65.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas PTCT's P/E ratio is 7.58. In terms of profitability, SRZNW's ROE is +6.11%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, SRZNW is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check PTCT's competition here
SRZNW vs CAI Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, CAI has a market cap of 5.4B. Regarding current trading prices, SRZNW is priced at $0.02, while CAI trades at $18.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas CAI's P/E ratio is -5.89. In terms of profitability, SRZNW's ROE is +6.11%, compared to CAI's ROE of +0.25%. Regarding short-term risk, SRZNW is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check CAI's competition here
SRZNW vs MIRM Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, MIRM has a market cap of 5.3B. Regarding current trading prices, SRZNW is priced at $0.02, while MIRM trades at $105.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas MIRM's P/E ratio is -203.48. In terms of profitability, SRZNW's ROE is +6.11%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, SRZNW is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check MIRM's competition here
SRZNW vs LEGN Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, LEGN has a market cap of 5.3B. Regarding current trading prices, SRZNW is priced at $0.02, while LEGN trades at $28.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas LEGN's P/E ratio is -17.60. In terms of profitability, SRZNW's ROE is +6.11%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, SRZNW is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for SRZNW.Check LEGN's competition here
SRZNW vs APLS Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, APLS has a market cap of 5.2B. Regarding current trading prices, SRZNW is priced at $0.02, while APLS trades at $40.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas APLS's P/E ratio is 227.72. In terms of profitability, SRZNW's ROE is +6.11%, compared to APLS's ROE of +0.08%. Regarding short-term risk, SRZNW is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check APLS's competition here
SRZNW vs FBIOX Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, SRZNW is priced at $0.02, while FBIOX trades at $25.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas FBIOX's P/E ratio is N/A. In terms of profitability, SRZNW's ROE is +6.11%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, SRZNW is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check FBIOX's competition here
SRZNW vs APGE Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, APGE has a market cap of 5.1B. Regarding current trading prices, SRZNW is priced at $0.02, while APGE trades at $83.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas APGE's P/E ratio is -19.72. In terms of profitability, SRZNW's ROE is +6.11%, compared to APGE's ROE of -0.37%. Regarding short-term risk, SRZNW is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check APGE's competition here
SRZNW vs CRSP Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, SRZNW is priced at $0.02, while CRSP trades at $52.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas CRSP's P/E ratio is -8.10. In terms of profitability, SRZNW's ROE is +6.11%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, SRZNW is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check CRSP's competition here
SRZNW vs TERN Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, SRZNW is priced at $0.02, while TERN trades at $52.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas TERN's P/E ratio is -51.42. In terms of profitability, SRZNW's ROE is +6.11%, compared to TERN's ROE of -0.20%. Regarding short-term risk, SRZNW is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check TERN's competition here
SRZNW vs MANE Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, MANE has a market cap of 4.7B. Regarding current trading prices, SRZNW is priced at $0.02, while MANE trades at $114.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas MANE's P/E ratio is -48.14. In terms of profitability, SRZNW's ROE is +6.11%, compared to MANE's ROE of -0.76%. Regarding short-term risk, SRZNW is more volatile compared to MANE. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check MANE's competition here
SRZNW vs LGND Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, LGND has a market cap of 4.6B. Regarding current trading prices, SRZNW is priced at $0.02, while LGND trades at $232.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas LGND's P/E ratio is 37.83. In terms of profitability, SRZNW's ROE is +6.11%, compared to LGND's ROE of +0.14%. Regarding short-term risk, SRZNW is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check LGND's competition here
SRZNW vs XENE Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, XENE has a market cap of 4.6B. Regarding current trading prices, SRZNW is priced at $0.02, while XENE trades at $57.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas XENE's P/E ratio is -13.23. In terms of profitability, SRZNW's ROE is +6.11%, compared to XENE's ROE of -0.56%. Regarding short-term risk, SRZNW is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check XENE's competition here
SRZNW vs FOLD Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, SRZNW is priced at $0.02, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas FOLD's P/E ratio is -161.00. In terms of profitability, SRZNW's ROE is +6.11%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, SRZNW is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check FOLD's competition here
SRZNW vs AKRO Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, SRZNW is priced at $0.02, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas AKRO's P/E ratio is -14.57. In terms of profitability, SRZNW's ROE is +6.11%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, SRZNW is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check AKRO's competition here
SRZNW vs ALPN Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, SRZNW is priced at $0.02, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas ALPN's P/E ratio is -101.52. In terms of profitability, SRZNW's ROE is +6.11%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, SRZNW is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check ALPN's competition here
SRZNW vs SYRE Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, SYRE has a market cap of 4.3B. Regarding current trading prices, SRZNW is priced at $0.02, while SYRE trades at $71.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas SYRE's P/E ratio is -35.83. In terms of profitability, SRZNW's ROE is +6.11%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, SRZNW is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check SYRE's competition here
SRZNW vs CRNX Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, CRNX has a market cap of 4.3B. Regarding current trading prices, SRZNW is priced at $0.02, while CRNX trades at $40.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas CRNX's P/E ratio is -8.23. In terms of profitability, SRZNW's ROE is +6.11%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, SRZNW is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check CRNX's competition here
SRZNW vs OPT Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, SRZNW is priced at $0.02, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas OPT's P/E ratio is -1.52. In terms of profitability, SRZNW's ROE is +6.11%, compared to OPT's ROE of +0.88%. Regarding short-term risk, SRZNW is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check OPT's competition here
SRZNW vs KNSA Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, KNSA has a market cap of 4.2B. Regarding current trading prices, SRZNW is priced at $0.02, while KNSA trades at $56.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas KNSA's P/E ratio is 59.74. In terms of profitability, SRZNW's ROE is +6.11%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, SRZNW is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check KNSA's competition here
SRZNW vs TVTX Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, TVTX has a market cap of 4.1B. Regarding current trading prices, SRZNW is priced at $0.02, while TVTX trades at $44.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas TVTX's P/E ratio is -89.66. In terms of profitability, SRZNW's ROE is +6.11%, compared to TVTX's ROE of -0.58%. Regarding short-term risk, SRZNW is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for SRZNW.Check TVTX's competition here
SRZNW vs MRTX Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, SRZNW is priced at $0.02, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas MRTX's P/E ratio is -4.82. In terms of profitability, SRZNW's ROE is +6.11%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, SRZNW is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check MRTX's competition here
SRZNW vs EWTX Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, EWTX has a market cap of 4.1B. Regarding current trading prices, SRZNW is priced at $0.02, while EWTX trades at $38.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas EWTX's P/E ratio is -23.33. In terms of profitability, SRZNW's ROE is +6.11%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, SRZNW is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check EWTX's competition here
SRZNW vs ACAD Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, SRZNW is priced at $0.02, while ACAD trades at $22.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas ACAD's P/E ratio is 9.71. In terms of profitability, SRZNW's ROE is +6.11%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, SRZNW is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check ACAD's competition here
SRZNW vs CPRX Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, SRZNW is priced at $0.02, while CPRX trades at $30.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas CPRX's P/E ratio is 18.36. In terms of profitability, SRZNW's ROE is +6.11%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, SRZNW is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check CPRX's competition here
SRZNW vs RYZB Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, SRZNW is priced at $0.02, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas RYZB's P/E ratio is -57.86. In terms of profitability, SRZNW's ROE is +6.11%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, SRZNW is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check RYZB's competition here
SRZNW vs TLX Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, TLX has a market cap of 3.7B. Regarding current trading prices, SRZNW is priced at $0.02, while TLX trades at $11.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas TLX's P/E ratio is -552.00. In terms of profitability, SRZNW's ROE is +6.11%, compared to TLX's ROE of -0.02%. Regarding short-term risk, SRZNW is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check TLX's competition here
SRZNW vs CBAY Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, SRZNW is priced at $0.02, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas CBAY's P/E ratio is -32.81. In terms of profitability, SRZNW's ROE is +6.11%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, SRZNW is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check CBAY's competition here
SRZNW vs VKTX Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, VKTX has a market cap of 3.6B. Regarding current trading prices, SRZNW is priced at $0.02, while VKTX trades at $31.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas VKTX's P/E ratio is -7.54. In terms of profitability, SRZNW's ROE is +6.11%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, SRZNW is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check VKTX's competition here
SRZNW vs SWTX Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, SRZNW is priced at $0.02, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas SWTX's P/E ratio is -13.78. In terms of profitability, SRZNW's ROE is +6.11%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, SRZNW is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check SWTX's competition here
SRZNW vs LQDA Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, LQDA has a market cap of 3.5B. Regarding current trading prices, SRZNW is priced at $0.02, while LQDA trades at $40.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas LQDA's P/E ratio is -50.14. In terms of profitability, SRZNW's ROE is +6.11%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, SRZNW is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check LQDA's competition here
SRZNW vs DNTH Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, DNTH has a market cap of 3.5B. Regarding current trading prices, SRZNW is priced at $0.02, while DNTH trades at $90.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas DNTH's P/E ratio is -21.48. In terms of profitability, SRZNW's ROE is +6.11%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, SRZNW is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check DNTH's competition here
SRZNW vs NAMS Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, NAMS has a market cap of 3.4B. Regarding current trading prices, SRZNW is priced at $0.02, while NAMS trades at $29.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas NAMS's P/E ratio is -17.38. In terms of profitability, SRZNW's ROE is +6.11%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, SRZNW is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check NAMS's competition here
SRZNW vs ALMS Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, ALMS has a market cap of 3.2B. Regarding current trading prices, SRZNW is priced at $0.02, while ALMS trades at $26.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas ALMS's P/E ratio is -9.11. In terms of profitability, SRZNW's ROE is +6.11%, compared to ALMS's ROE of -0.73%. Regarding short-term risk, SRZNW is more volatile compared to ALMS. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check ALMS's competition here
SRZNW vs KLRA Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, KLRA has a market cap of 3.1B. Regarding current trading prices, SRZNW is priced at $0.02, while KLRA trades at $24.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas KLRA's P/E ratio is -19.06. In terms of profitability, SRZNW's ROE is +6.11%, compared to KLRA's ROE of N/A. Regarding short-term risk, SRZNW is more volatile compared to KLRA. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check KLRA's competition here
SRZNW vs ERAS Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, ERAS has a market cap of 3.1B. Regarding current trading prices, SRZNW is priced at $0.02, while ERAS trades at $9.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas ERAS's P/E ratio is -22.73. In terms of profitability, SRZNW's ROE is +6.11%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, SRZNW is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check ERAS's competition here
SRZNW vs DNLI Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, DNLI has a market cap of 3B. Regarding current trading prices, SRZNW is priced at $0.02, while DNLI trades at $18.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas DNLI's P/E ratio is -6.37. In terms of profitability, SRZNW's ROE is +6.11%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, SRZNW is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check DNLI's competition here
SRZNW vs ANAB Comparison May 2026
SRZNW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRZNW stands at 157K. In comparison, ANAB has a market cap of 3B. Regarding current trading prices, SRZNW is priced at $0.02, while ANAB trades at $69.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRZNW currently has a P/E ratio of N/A, whereas ANAB's P/E ratio is -150.61. In terms of profitability, SRZNW's ROE is +6.11%, compared to ANAB's ROE of +18.14%. Regarding short-term risk, SRZNW is more volatile compared to ANAB. This indicates potentially higher risk in terms of short-term price fluctuations for SRZNW.Check ANAB's competition here